evidence table
Resveratrol Insulin Sensitivity Randomized Trial Evidence Table
Structured evidence table for Resveratrol Insulin Sensitivity Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Resveratrol Insulin Sensitivity Randomized Trial | The main aim of this systematic review is to comprehensively evaluate and synthesize the current scientific evidence on the role of anthocyanins, curcumin, and resveratrol in the prevention and management of metabolic disorders, with a focus on obesity, type 2 diabetes, and dyslipidemia. | 1 | Gazda P (2026) | The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review. |
| Resveratrol Insulin Sensitivity Randomized Trial | The analyzed studies demonstrated that anthocyanin supplementation (up to 320 mg/day) was associated with reductions in inflammatory markers such as IL-6 and TNF-α, improvements in HDL cholesterol, and modest reductions in HbA1c (~0.3-0.5%). | 1 | Gazda P (2026) | The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review. |
| Resveratrol Insulin Sensitivity Randomized Trial | Curcumin supplementation was associated with decreases in body weight (up to 0.82 kg), BMI (up to 0.30 kg/m 2 ), triglycerides, total cholesterol, and fasting glucose levels. | 1 | Gazda P (2026) | The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review. |
| Resveratrol Insulin Sensitivity Randomized Trial | Metabolic disorders such as obesity, type 2 diabetes, and lipid disorders are major health challenges worldwide. | 1 | Gazda P (2026) | The Role of Anthocyanins, Curcumin, and Resveratrol in the Prevention and Management of Metabolic Disorders: A Systematic Review. |
| Resveratrol Insulin Sensitivity Randomized Trial | The aim of this systematic review was to synthesize available evidence regarding the metabolic and pancreatic effects of resveratrol in diabetes mellitus. | 1 | Meden A (2026) | Resveratrol in diabetes and pancreatic function: implications for the exocrine-endocrine pancreatic axis-a systematic review. |
| Resveratrol Insulin Sensitivity Randomized Trial | Evidence from experimental and clinical studies indicates that resveratrol may improve glycemic control, attenuate inflammatory responses, reduce oxidative stress, and protect pancreatic β-cell function, primarily through activation of signaling pathways such as sirtuin-1 (SIRT1) and AMP-activated protein kinase (AMPK). | 1 | Meden A (2026) | Resveratrol in diabetes and pancreatic function: implications for the exocrine-endocrine pancreatic axis-a systematic review. |
| Resveratrol Insulin Sensitivity Randomized Trial | Most available evidence originates from studies in type 2 diabetes mellitus or experimental models of diabetes. | 1 | Meden A (2026) | Resveratrol in diabetes and pancreatic function: implications for the exocrine-endocrine pancreatic axis-a systematic review. |
| Resveratrol Insulin Sensitivity Randomized Trial | Pancreatic dysfunction plays an important role in the development and progression of diabetes mellitus. | 1 | Meden A (2026) | Resveratrol in diabetes and pancreatic function: implications for the exocrine-endocrine pancreatic axis-a systematic review. |
Source documents